Wikia

Psychology Wiki

Antiviral drugs

Talk0
34,117pages on
this wiki

Assessment | Biopsychology | Comparative | Cognitive | Developmental | Language | Individual differences | Personality | Philosophy | Social |
Methods | Statistics | Clinical | Educational | Industrial | Professional items | World psychology |

Biological: Behavioural genetics · Evolutionary psychology · Neuroanatomy · Neurochemistry · Neuroendocrinology · Neuroscience · Psychoneuroimmunology · Physiological Psychology · Psychopharmacology (Index, Outline)


This is a background article. For psychological research in this area see:

Main article: Psychological issues with antiretroviral drug use in HIV/AIDS

Antiviral drugs are a class of medication used specifically for treating viral infections. Like antibiotics for bacteria, specific antivirals are used for specific viruses. Antiviral drugs are one class of antimicrobials, a larger group which also includes antibiotic, antifungal and antiparasitic drugs. They are relatively harmless to the host, and therefore can be used to treat infections. They should be distinguished from viricides, which actively destroy virus particles outside the body.

Most of the antivirals now available are designed to help deal with HIV, herpes viruses (best known for causing cold sores and genital herpes, but actually causing a wide range of diseases), the hepatitis B and C viruses, which can cause liver cancer, and influenza A and B viruses. Researchers are now working to extend the range of antivirals to other families of pathogens.

Designing safe and effective antiviral drugs is difficult, because viruses use the host's cells to replicate. This makes it difficult to find targets for the drug that would interfere with the virus without harming the host organism's cells.

The emergence of antivirals is the product of a greatly expanded knowledge of the genetic and molecular function of organisms, allowing biomedical researchers to understand the structure and function of viruses, major advances in the techniques for finding new drugs, and the intense pressure placed on the medical profession to deal with the human immunodeficiency virus (HIV), the cause of the deadly acquired immunodeficiency syndrome (AIDS) pandemic.

Almost all anti-microbials, including anti-virals, are subject to drug resistance as the pathogens evolve to survive exposure to the treatment.

History Edit

Modern medical science and practice has an array of effective tools, ranging from antiseptics to vaccines and antibiotics. One field in which medicine has historically been weak, however, is in finding drugs to deal with viral infections. Highly effective vaccines have been recently developed to prevent such diseases, but formerly, when someone contracted a virus, there was little that could be done but to recommend rest and plenty of fluids until the disease ran its course.

The first experimental antivirals were developed in the 1960s, mostly to deal with herpes viruses, and were found using traditional trial-and-error drug discovery methods. Researchers grew cultures of cells and infected them with the target virus. They then introduced chemicals into the cultures they thought were likely to inhibit viral activity, and observed whether the level of virus in the cultures rose or fell. Chemicals that seemed to have an effect were selected for closer study.

This was a very time-consuming, hit-or-miss procedure, and in the absence of a good knowledge of how the target virus worked, it was not efficient in discovering antivirals that were effective and had few side effects. It was not until the 1980s, when the full genetic sequences of viruses began to be unraveled, that researchers began to learn how viruses worked in detail, and exactly what chemicals were needed to thwart their reproductive cycle. Dozens of antiviral treatments are now available, and medical research is rapidly exploiting new knowledge and technology to develop more.

Virus life cycle Edit

Viruses consist of a genome and sometimes a few enzymes stored in a capsule made of protein (called a capsid), and sometimes covered with a lipid layer (sometimes called an 'envelope'). Viruses cannot reproduce on their own, so they propagate by subjugating a host cell to produce copies of themselves, thus producing the next generation.

Researchers working on such "rational drug design" strategies for developing antivirals have tried to attack viruses at every stage of their life cycles. Viral life cycles vary in their precise details depending on the species of virus, but they all share a general pattern:

  • Attachment to a host cell.
  • Release of viral genes and possibly enzymes into the host cell.
  • Replication of viral components using host-cell machinery.
  • Assembly of viral components into complete viral particles.
  • Release of viral particles to infect new host cells.

Inadequacy of vaccinesEdit

Vaccines bolster the body's immune system to better attack viruses in the "complete particle" stage, outside of the organism's cells. They traditionally consist of an attenuated (weakened or killed) version of the virus. The vaccine can still cause harm to the host, namely by inadvertently infecting the host with a full-blown viral occupancy. Recently "subunit" vaccines have been devised that consist strictly of protein targets from the pathogen. They stimulate the immune system without doing serious harm to the host. In either case, when the real pathogen attacks the subject, the immune system responds to it quickly and blocks it.

Vaccines are very effective on stable viruses, but are of limited use in treating a patient who has already been infected. They are also difficult to successfully deploy against rapidly mutating viruses, such as influenza (the vaccine for which is updated every year) and HIV. These two gaps are where antiviral drugs become useful.

Anti-viral targeting techniqueEdit

The general idea behind modern antiviral drug design is to identify viral proteins, or parts of proteins, that can be disabled. These "targets" should generally be as unlike any proteins or parts of proteins in humans as possible, to reduce the likelihood of side effects. The targets should also be common across many strains of a virus, or even among different species of virus in the same family, so a single drug will have broad effectiveness. For example, a researcher might target a critical enzyme synthesized by the virus, but not the patient, that is common across strains, and see what can be done to interfere with its operation.

Once targets are identified, candidate drugs can be selected, either from drugs already known to have appropriate effects, or by actually designing the candidate at the molecular level with a computer-aided design program.

The target proteins can be manufactured in the lab for testing with candidate treatments by inserting the gene that synthesizes the target protein into bacteria or other kinds of cells. The cells are then cultured for mass production of the protein, which can then be exposed to various treatment candidates and evaluated with "rapid screening" technologies.

Approaches by life cycle stageEdit

Before cell entryEdit

One anti-viral strategy is to interfere with the ability of a virus to infiltrate a target cell. The virus must go through a sequence of steps to do this, beginning with binding to a specific "receptor" molecule on the surface of the host cell and ending with the virus "uncoating" inside the cell and releasing its contents. Viruses that have a lipid envelope must also fuse their envelope with the target cell, or with a vesicle that transports them into the cell, before they can uncoat.

This stage of viral replication can be inhibited in two ways: 1. Using agents which mimic the virus-associated protein (VAP) and bind to the cellular receptors. This may include VAP anti-idiotypic antibodies, natural ligands of the receptor and anti-receptor antibodies.[clarify]


2. Using agents which mimic the cellular receptor and bind to the VAP. This includes anti-VAP antibodies, receptor anti-idiotypic antibodies, extraneous receptor and synthetic receptor mimics.

This strategy of designing drugs can be very expensive, and since the process of generating anti-idiotypic antibodies is partly trial and error, it can be a relatively slow process until an adequate molecule is produced.

A very early stage of viral infection is viral entry, when the virus attaches to and enters the host cell. A number of "entry-inhibiting" or "entry-blocking" drugs are being developed to fight HIV. HIV most heavily targets the immune system white blood cells known as "helper T cells", and identifies these target cells through T-cell surface receptors designated "CD4" and "CCR5". Attempts to interfere with the binding of HIV with the CD4 receptor have failed to stop HIV from infecting helper T cells, but research continues on trying to interfere with the binding of HIV to the CCR5 receptor in hopes that it will be more effective.

However, two entry-blockers, amantadine and rimantadine, have been introduced to combat influenza, and researchers are working on entry-inhibiting drugs to combat hepatitis B and C virus.

One entry-blocker is pleconaril. Pleconaril works against rhinoviruses, which cause the common cold, by blocking a pocket on the surface of the virus that controls the uncoating process. This pocket is similar in most strains of rhinoviruses and enteroviruses, which can cause diarrhea, meningitis, conjunctivitis, and encephalitis.

During viral synthesisEdit

A second approach is to target the processes that synthesize virus components after a virus invades a cell. One way of doing this is to develop nucleotide or nucleoside analogues that look like the building blocks of RNA or DNA, but deactivate the enzymes that synthesize the RNA or DNA once the analogue is incorporated.

The first successful antiviral, acyclovir, is a nucleoside analogue, and is effective against herpesvirus infections. The first antiviral drug to be approved for treating HIV, zidovudine (AZT), is also a nucleoside analogue.

An improved knowledge of the action of reverse transcriptase has led to better nucleoside analogues to treat HIV infections. One of these drugs, lamivudine, has been approved to treat hepatitis B, which uses reverse transcriptase as part of its replication process. Researchers have gone further and developed inhibitors that do not look like nucleosides, but can still block reverse transcriptase.

Other targets being considered for HIV antivirals include RNase H - which is a component of reverse transcriptase that splits the synthesized DNA from the original viral RNA - and integrase, which splices the synthesized DNA into the host cell genome.

Once a virus genome becomes operational in a host cell, it then generates messenger RNA (mRNA) molecules that direct the synthesis of viral proteins. Production of mRNA is initiated by proteins known as transcription factors. Several antivirals are now being designed to block attachment of transcription factors to viral DNA.

Genomics has not only helped find targets for many antivirals, it has provided the basis for an entirely new type of drug, based on "antisense" molecules. These are segments of DNA or RNA that are designed as "mirror images" to critical sections of viral genomes, and the binding of these antisense segments to these target sections blocks the operation of those genomes. A phosphorothioate antisense drug named fomivirsen has been introduced, used to treat opportunistic eye infections in AIDS patients caused by cytomegalovirus, and other antisense antivirals are in development. An antisense structural type that has proven especially valuable in research is morpholino antisense. Morpholino oligos have been used to experimentally suppress many viral types including caliciviruses [1], flaviviruses (including WNV [2] , Dengue [3] and HCV [4] ), and coronaviruses [5] and are currently in clinical development.

Yet another antiviral technique inspired by genomics is a set of drugs based on ribozymes, which are enzymes that will cut apart viral RNA or DNA at selected sites. In their natural course, ribozymes are used as part of the viral manufacturing sequence, but these synthetic ribozymes are designed to cut RNA and DNA at sites that will disable them.

A ribozyme antiviral to deal with hepatitis C is in field testing, and ribozyme antivirals are being developed to deal with HIV. An interesting variation of this idea is the use of genetically modified cells that can produce custom-tailored ribozymes. This is part of a broader effort to create genetically modified cells that can be injected into a host to attack pathogens by generating specialized proteins that block viral replication at various phases of the viral life cycle.

Some viruses include an enzyme known as a protease that cuts viral protein chains apart so they can be assembled into their final configuration. HIV includes a protease, and so considerable research has been performed to find "protease inhibitors" to attack HIV at that phase of its life cycle. Protease inhibitors became available in the 1990s and have proven effective, though they can have unusual side effects, for example causing fat to build up in unusual places. Improved protease inhibitors are now in development.

Release phaseEdit

The final stage in the life cycle of a virus is the release of completed viruses from the host cell, and this step has also been targeted by antiviral drug developers. Two drugs named zanamivir (Relenza) and oseltamivir (Tamiflu) that have been recently introduced to treat influenza prevent the release of viral particles by blocking a molecule named neuraminidase that is found on the surface of flu viruses, and also seems to be constant across a wide range of flu strains.

Immune system stimulationEdit

A second category of tactics for fighting viruses involves encouraging the body's immune system to attack them, rather than attacking them directly. Some antivirals of this sort do not focus on a specific pathogen, instead stimulating the immune system to attack a range of pathogens.

One of the best-known of this class of drugs are interferons, which inhibit viral synthesis in infected cells. One form of human interferon named "interferon alpha" is well-established as a treatment for hepatitis B and C, and other interferons are also being investigated as treatments for various diseases.

A more specific approach is to synthesize antibodies, protein molecules that can bind to a pathogen and mark it for attack by other elements of the immune system. Once researchers identify a particular target on the pathogen, they can synthesize quantities of identical "monoclonal" antibodies to link up that target. A monoclonal drug is now being sold to help fight respiratory syncytial virus in babies, and another is being tested as a treatment for hepatitis B.

Examination of the genomes of viruses and comparison with the human genome show that some generate proteins that mimic those used by the human immune system, confusing the immune system response. Researchers are now searching for antivirals that can recognize these intruder proteins and disable them.

See alsoEdit

ReferencesEdit


Further readingEdit

  • Abdel-Salam, O. M. E. (2006). Antinociceptive and behavioral effects of ribavirin in mice: Pharmacology, Biochemistry and Behavior Vol 83(2) Feb 2006, 230-238.
  • Ahuja, N. (2007). Azithromycin and catatonic symptoms: Journal of Clinical Psychiatry Vol 68(2) Feb 2007, 336-337.
  • Chuck, S. K., Rodvold, K. A., Moltke, L. L. v., Greenblatt, D. J., & Shader, R. I. (1999). Pharmacokinetics of protease inhibitors and drug interactions with psychoactive drugs. Dordrecht, Netherlands: Kluwer Academic Publishers.
  • Das, S. K., Pareek, A., Mathur, D. S., Wanchu, A., Srivastava, R., Agarwal, G. G., et al. (2007). Efficacy and safety of hydroxychloroquine sulphate in rheumatoid arthritis: A randomized, double-blind, placebo controlled clinical trial: An Indian experience: Current Medical Research and Opinion Vol 23(9) Sep 2007, 2227-2234.
  • Dieperink, E., Leskela, J., Dieperink, M. E., Evans, B., Thuras, P., & Ho, S. B. (2008). The effect of pegylated interferon-alpha -sub(2b) and Ribavirin on posttraumatic stress disorder symptoms: Psychosomatics: Journal of Consultation Liaison Psychiatry Vol 49(3) May-Jun 2008, 225-229.
  • Douglas, S. D. (2005). Hepatitis C, depressive symptoms, viral load, and therapy: Interactions and reactions: Brain, Behavior, and Immunity Vol 19(1) Jan 2005, 20-22.
  • Hargrave, D. R., & Webb, D. W. (1998). Movement disorders in association with herpes simplex virus encephalitis in children: A review: Developmental Medicine & Child Neurology Vol 40(9) Sep 1998, 640-642.
  • Kaplan, C. P., & Bain, K. P. (1999). Cognitive outcome after emergent treatment of acute herpes simplex encephalitis with acyclovir: Brain Injury Vol 13(11) Nov 1999, 935-941.
  • Lacobellis, G., Pellicelli, A. M., Grisorio, B., Barbarini, G., Leonetti, F., Sharma, A. M., et al. (2008). Relation of epicardial fat and alanine aminotransferase in subjects with increased visceral fat: Obesity Vol 16(1) Jan 2008, 179-183.
  • Mathis, S., Gil, R., & Neau, J. P. (2006). Neurological complications of Herpes zoster: Revue Neurologique Vol 162(8-9) Sep 2006, 879-887.
  • Matthews, A. M., Fireman, M., Zucker, B., Sobel, M., & Hauser, P. (2006). Relapse to Opioid Use After Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin: American Journal of Psychiatry Vol 163(8) Aug 2006, 1342-1347.
  • McCance-Katz, E. F., Farber, S., Selwyn, P. A., & O'Connor, A. (2000). Decrease in methadone levels with nelfinavir mesylate: American Journal of Psychiatry Vol 157(3) Mar 2000, 481.
  • Morasco, B. J., Rifai, M. A., Loftis, J. M., Indest, D. W., Moles, J. K., & Hauser, P. (2007). A randomized trial of paroxetine to prevent interferon-alpha -induced depression in patients with hepatitis C: Journal of Affective Disorders Vol 103(1-3) Nov 2007, 83-90.
  • Opstelten, W., van Essen, G. A., Moons, K. G. M., van Wijck, A. J. M., Schellevis, F. G., Kalkman, C. J., et al. (2005). Do herpes zoster patients receive antivirals? A Dutch national survey in general practice: Family Practice Vol 22(5) Oct 2005, 523-528.
  • Pacifici, G. M. (2005). Pharmacokinetics of antivirals in neonate: Early Human Development Vol 81(9) Sep 2005, 773-780.
  • Raison, C. L., Broadwell, S. D., Borisov, A. S., Manatunga, A. K., Capuron, L., Woolwine, B. J., et al. (2005). Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C: Brain, Behavior, and Immunity Vol 19(1) Jan 2005, 23-27.
  • Raison, C. L., Capuron, L., & Miller, A. H. (2005). Depressive symptoms and viral clearance: In response: Brain, Behavior, and Immunity Vol 19(4) Jul 2005, 273-274.


DissertationsEdit

  • Fowler, C. L. (2007). Illness representations, coping, and quality of life in patients with hepatitis C undergoing antiviral therapy. Dissertation Abstracts International: Section B: The Sciences and Engineering.



Template:HIVpharm

This page uses Creative Commons Licensed content from Wikipedia (view authors).

Around Wikia's network

Random Wiki